Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Safety and Reactogenicity of FluBlok, Trivalent Recombinant Influenza Vaccine, and Comparison of the Immunogenicity, Efficacy and Effectiveness of FluBlok to a Licensed Egg-Grown Influenza Vaccine in Adults Aged 50 to 64

NCT00539864 is registered in ClinicalTrials.gov with Protein Sciences Corporation as lead sponsor.

NCT NCT00539864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00539864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Safety and Reactogenicity of FluBlok, Trivalent Recombinant Influenza Vaccine, and Comparison of the Immunogenicity, Efficacy and Effectiveness of FluBlok to a Licensed Egg-Grown Influenza Vaccine in Adults Aged 50 to 64
Lead sponsor
Protein Sciences Corporation
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2007
Completion date
April 30, 2008
Enrollment
602 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

influenza